When was Stemgent founded?

Stemgent was founded in 2008 and raised its 1st funding round within a year of its incorporation.

Where is Stemgent located?

Stemgent is headquartered in Cambridge, United States.

How many employees does Stemgent have?

As of Sep 30, 2026, the latest employee count at Stemgent is 11.

Is Stemgent a funded company?

Stemgent is a funded company, having raised a total of $43.2M across 9 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on May 2008.

When was the latest funding round of Stemgent?

Stemgent's latest funding was a $***** Series B round on Aug 06, 2012, with participation from 0 investor. Its primary sector is Life Sciences Platforms and Tools. In United States, the Life Sciences Platforms and Tools sector has seen $1.8B in funding in 2026 to date.

Where does Stemgent rank among its competitors?

Stemgent ranks 414th amongst 2051 active competitors, of which 449 are funded. It stands 8th in terms of total funding among its competitors. The most recent competitor to raise funding was One Biosciences, which secured $3.76M in Sep, 2026.

Who are the top competitors of Stemgent?

Stemgent's top competitors include Antheia, Synthego and Axol Bioscience. Among them, One Biosciences secured the most recent funding round in September, 2026.

Stemgent - 2026 Company Profile, Funding & Competitors

Company Details

Accelerating drug discovery and regenerative medicine through stem cell and tissue technologies. The company provides comprehensive services and products for preclinical and clinical research, focusing on stem cell technologies, drug discovery, and analytical services. It offers a wide range of solutions, including stem cell services, gene editing, precision medicine, preclinical drug development, clinical laboratory services, human tissue samples, and genomic services. The company also provides cells and products for stem cell research and 3D cell culture, including stem cell reagents, cells, 3D cell culture systems, and labware. The company supports scientists in translating their research into therapies, offering expertise in patient recruitment, human biospecimens, and diagnostics. The company is committed to improving human health through biomedical innovation and discovery, offering tools and services that de-risk, enable, and accelerate customer research workflows and medical healthcare applications.

Website: stemgent.com
Social

Key Metrics

Founded Year

2008

Location

Cambridge, United States

Stage

Acqui-Hired

Total Funding

$43.2M in 9 rounds

Latest Funding Round

Series B, Aug 06, 2012, $*****

Investors

Lightstone Ventures & 2 more

Ranked

414^th among 2051 active competitors

Employee Count

11 as on Sep 30, 2026

Similar Companies

Antheia & 2757 more

View Stemgent's full profile

Stemgent has raised a total funding of $43.2M over 9 rounds. Its first funding round was on May 2008. Stemgent has 3 institutional investors.

Here is the list of recent funding rounds of Stemgent:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Aug 06, 2012	4422238	Series B	8557964	2552613	3671399	7152599
Jan 30, 2012	9121236	Series B	9298382	7982938	6582698	4318798
Oct 26, 2011	8535801	Conventional Debt	6400292	9740647	7671790	5229538

Access funding benchmarks and valuations. Sign up today!

View details of Stemgent's funding rounds and investors

Stemgent's employee count trend

Stemgent has 11 employees as of Sep 26. Here is Stemgent's employee count trend over the years:

Uncover Stemgent's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Stemgent include Antheia, Synthego and Axol Bioscience. Here is the list of Top 10 competitors of Stemgent, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Antheia 2013, Palo Alto (United States), Series C	Genetically engineered yeast cells to produce medicinal products	$176M	Viking Global Investors, ATHOS KG & 15 others	68/100
2nd	Synthego 2012, Redwood City (United States), Acquired	Manufacturer of custom CRISPR gene editors and molecular biology reagents	$460M	8VC, Perceptive Advisors & 31 others	67/100
3rd	Axol Bioscience 2013, Cambridge (United Kingdom), Series A	Provider of human cells, reagents, and reprogramming services	$13.3M	Calculus Capital, Scottish Enterprise & 13 others	65/100
4th	Akeso 2012, Zhongshan (China), Public	Developer of antibody drug conjugates for the treatment of broad spectrum diseases	$195M	Loayal Valley Capital, Sino Biopharmaceutical ... & 18 others	65/100
5th	Korro Bio 2018, Cambridge (United States), Public	Provider of RNA editing technologies to develop genetic medicines for rare and prevalent diseases	$4M	Cormorant Asset Management, Atlas Venture ... & 15 others	64/100
6th	Novogene Corporation 2011, Beijing (China), Series B	Provider of genomic services and solutions	$75M	SDIC Innovation, CMB International Capital ... & 4 others	64/100
7th	Avalyn Pharma 2011, Seattle (United States), Public	Developer of therapies for the treatment of Idiopathic Pulmonary Fibrosis	$389M	Perceptive Advisors, Norwest & 22 others	63/100
8th	enGene 1999, Saint laurent (Canada), Public	Developer of oral non-viral gene therapy platform	$54M	Hercules Capital, Lumira Ventures & 15 others	63/100
9th	Watchmaker Genomics 2018, Boulder (United States), Series A	Developer of gene-editing technology	$48.3M	Decheng Capital, Eclipse	63/100
10th	One Biosciences 2020, Paris (France), Series A	Developer of single-cell therapeutics solutions to treat multiple health disorders	$22.4M	BLAST Premier, Redmile Group & 7 others	63/100
414th	Stemgent 2008, Cambridge (United States), Acqui-Hired	Accelerating drug discovery and regenerative medicine through stem cell and tissue technologies	$43.2M	Lightstone Ventures, Healthcare Ventures & 1 others	35/100